Introduction Advanced stage malignant mesothelioma (asMM) patients have poor prognosis.
Several trials investigated the role of programmed cell death protein-1 (PD-1) and its ligand …

Lung cancer care is rapidly changing with advances in genomic testing, the development of
next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy …

V-domain Ig-containing suppressor of T-cell activation (VISTA) is an immune checkpoint
gene that inhibits anti-tumor immune responses. Since most malignant pleural …

Aims There is robust trial evidence for improved overall survival (OS) with immunotherapy in
advanced solid organ malignancies. The real‐world long‐term survival data and the …

Objectives Currently, there is no optimal salvage therapy for patients with malignant pleural
mesothelioma (MPM) who relapse after treatment with first-line chemotherapy. In line with …

The world currently faces a pandemic due to SARS-CoV-2. Relevant information has
emerged regarding the higher risk of poor outcomes in lung cancer patients. As such, lung …

Measurements of K0 meson and Λ baryon production in deep-inelastic positron-proton
scattering (DIS) are presented in the kinematic range 10< Q2< 70 GeV2 and 10− 4< x< 10 …

Malignant pleural mesothelioma (MPM) is a rare malignant tumor arising from the serous
surface of the pleura and accounting for less than 0.3% of all cancers. MPM is highly …

Malignant pleural mesothelioma (MPM) is a global health issue, the principal cause of which
is exposure to asbestos. The prevalence is anticipated to rise over the next 2 decades …

In light of the promising results of immune checkpoint blockade (ICPB) in malignant pleural
mesothelioma (MPM), we investigated the effect of different chemotherapeutic agents on the …